The US Food and Drug Administration and Covis Pharma are navigating uncharted waters with the agency-ordered withdrawal of preterm birth prevention drug Makena (hydroxyprogesterone caproate) for lack of demonstrated efficacy.
Makena’s label carried only one indication – to reduce the risk of preterm birth in women with a singleton pregnancy...








